Interestingly, overexpression of MEF2C was also observed in pretreatment bone marrow specimens from acute myeloid leukemia patients, which was correlated with MEF2C protein expression, suggesting a contribution to the aggressive nature of at least some subtypes of the disease (Laszlo et al., 2015). This evidence concerns the gene MEF2C and acute myeloid leukemia.